drugset / Trial / NCT07408869
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Timeline
- Start
- 2026-04
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cizutamig | Protein / enzyme biologic | — | Subcutaneous |